Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 26.31
1.71 %
$ 1.92 B
Market Cap
-10.19
P/E
1. INTRINSIC VALUE
Balance Sheet
Schrödinger, Inc.
| Current Assets | 635 M |
| Cash & Short-Term Investments | 352 M |
| Receivables | 255 M |
| Other Current Assets | 27.5 M |
| Non-Current Assets | 188 M |
| Long-Term Investments | 43.2 M |
| PP&E | 136 M |
| Other Non-Current Assets | 8.95 M |
| Current Liabilities | 192 M |
| Accounts Payable | 10.7 M |
| Short-Term Debt | 16.8 M |
| Other Current Liabilities | 164 M |
| Non-Current Liabilities | 210 M |
| Long-Term Debt | 101 M |
| Other Non-Current Liabilities | 109 M |
EFFICIENCY
Earnings Waterfall
Schrödinger, Inc.
| Revenue | 208 M |
| Cost Of Revenue | 75.5 M |
| Gross Profit | 132 M |
| Operating Expenses | 341 M |
| Operating Income | -209 M |
| Other Expenses | -22.2 M |
| Net Income | -187 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Schrödinger, Inc.
| Net Income | -187 M |
| Depreciation & Amortization | 6.16 M |
| Capital Expenditures | -7.31 M |
| Stock-Based Compensation | 49.9 M |
| Change in Working Capital | -13 M |
| Others | 150 M |
| Free Cash Flow | -165 M |
Wall Street Analysts Price Targets
Schrödinger, Inc.
Wall Street analysts predict an average 1-year price target for SDGR of $28.5 , with forecasts ranging from
a
low of
$27 to a high of $30 .
SDGR Lowest Price Target
Wall Street Target
27 USD
2.62%
SDGR Average Price Target
Wall Street Target
28.5 USD
8.32%
SDGR Highest Price Target
Wall Street Target
30 USD
14.03%
4. DIVIDEND
ANALYSIS
SDGR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Schrödinger, Inc.
Sold
0-3 MONTHS
759 K USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
27.2 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Momentum Stocks That Could Soar Post-Market Volatility
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
marketbeat.com
- 1 week ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
businesswire.com
- 2 weeks ago
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur.
businesswire.com
- 2 weeks ago
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
- 2 weeks ago
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety.
seekingalpha.com
- 2 weeks ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
businesswire.com
- 1 month ago
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.
businesswire.com
- 1 month ago
Schrödinger: Still Waiting On A Catalyst
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing.
seekingalpha.com
- 2 months ago
Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Kyle Yang - Jefferies CJ Yeh - Leerink Partners Brendan Smith - TD Cowen Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Malcolm Hoffman - BMO Capital Markets Matt Hewitt - Craig-Hallum Capital Group Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's conference call to review Fourth Quarter and Full Year 2024 Financial Results.
seekingalpha.com
- 2 months ago
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
zacks.com
- 2 months ago
Schrödinger to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” sectio.
businesswire.com
- 2 months ago
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close.
businesswire.com
- 2 months ago
8. Profile
Summary
Schrödinger, Inc. SDGR
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 1.92 B
Dividend Yield
0.00%
Description
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Contact
1540 Broadway, New York, NY, 10036
https://www.schrodinger.com
IPO
Date
Feb. 6, 2020
Employees
891
Officers
Mr. Shane Brauner
Executive Vice President & Chief Information Officer
Dr. Geoffrey Craig Porges MBBS
Executive Vice President & Chief Financial Officer
Dr. Robert Lorne Abel Ph.D.
Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D
Prof. William Goddard III
Co-Founder & Scientific Advisor
Dr. Ramy Farid Ph.D.
Chief Executive Officer, President & Director
Dr. Richard A. Friesner Ph.D.
Co-Founder, Scientific Advisory Chairman and Director
Dr. Margaret Han Dugan M.D.
Chief Medical Officer
Mr. Kenneth Patrick Lorton
Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software
Ms. Jaren Irene Madden
Senior Vice President of Investor Relations & Corporate Affairs
Dr. Karen Akinsanya Ph.D.
President of Research & Development Therapeutics